Working group

Translational Virology

Short description

Besides analysing replication mechanisms of hepatitis B (HBV) and D (HDV) viruses, the focus of Professor Stephan Urban and his team is to develop new drugs against these pathogens. With Myrcludex B, which blocks the entry of viruses into the liver cell, a substance has already been taken from basic research to approval for HBV/HDV co-infected patients: The drug was approved for hepatitis D patients by the European Commission in July 2020 under the trade name "Hepcludex". The possibilities for use in hepatitis B without co-infection are still being examined. In addition, the research group is developing new testing systems for identifying further substances from compound libraries, which have already contributed towards the identification of new antiviral substances.

Research areas
Institutions
Partner Sites
Contact person

Prof. Dr. Stephan Urban

Heidelberg University
Deputy Coordinator Hepatitis
DZIF Professor "Translational Virology"
Partner Site Speaker Heidelberg

Articles on the working group